Meeting Report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency

K. S. Vannice, B. K. Giersing, D. C. Kaslow, E. Griffiths, H. Meyer, A. Barrett, A. P. Durbin, D. Wood, J. Hombach

Research output: Contribution to journalArticle

Abstract

On 1 February 2016, in the context of the ongoing Zika virus epidemic, the WHO declared that the recently reported clusters of microcephaly and other neurological disorders constituted a Public Health Emergency of International Concern (PHEIC). In response, WHO in collaboration with UNICEF and a working group of independent subject matter experts developed a Zika virus vaccine Target Product Profile (TPP) for use in an emergency, or in a future outbreak scenario. The drafting process of the Zika virus vaccine TPP included the opportunity for public comment, as well as consultation with epidemiologists, flavivirus vaccine subject matter experts, vaccine developers and global regulators to consider the regulatory expectations and potential emergency use pathways for a vaccine with the characteristics described in the TPP. This report summarizes an expert consultation held 6-7 June 2016 on the regulatory considerations for a Zika vaccine for emergency use.

Original languageEnglish (US)
Pages (from-to)7443-7450
Number of pages8
JournalVaccine
Volume37
Issue number50
DOIs
StatePublished - Nov 28 2019

Fingerprint

Zika virus
Emergencies
Referral and Consultation
Vaccines
vaccines
Flavivirus
Microcephaly
nervous system diseases
United Nations
Nervous System Diseases
Disease Outbreaks
Zika Virus
public health
Public Health

Keywords

  • Vaccine regulation
  • Zika vaccines
  • Zika virus

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Vannice, K. S., Giersing, B. K., Kaslow, D. C., Griffiths, E., Meyer, H., Barrett, A., ... Hombach, J. (2019). Meeting Report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency. Vaccine, 37(50), 7443-7450. https://doi.org/10.1016/j.vaccine.2016.10.034

Meeting Report : WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency. / Vannice, K. S.; Giersing, B. K.; Kaslow, D. C.; Griffiths, E.; Meyer, H.; Barrett, A.; Durbin, A. P.; Wood, D.; Hombach, J.

In: Vaccine, Vol. 37, No. 50, 28.11.2019, p. 7443-7450.

Research output: Contribution to journalArticle

Vannice, KS, Giersing, BK, Kaslow, DC, Griffiths, E, Meyer, H, Barrett, A, Durbin, AP, Wood, D & Hombach, J 2019, 'Meeting Report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency', Vaccine, vol. 37, no. 50, pp. 7443-7450. https://doi.org/10.1016/j.vaccine.2016.10.034
Vannice, K. S. ; Giersing, B. K. ; Kaslow, D. C. ; Griffiths, E. ; Meyer, H. ; Barrett, A. ; Durbin, A. P. ; Wood, D. ; Hombach, J. / Meeting Report : WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency. In: Vaccine. 2019 ; Vol. 37, No. 50. pp. 7443-7450.
@article{960dabf1cf3642218c27131c75ba36ea,
title = "Meeting Report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency",
abstract = "On 1 February 2016, in the context of the ongoing Zika virus epidemic, the WHO declared that the recently reported clusters of microcephaly and other neurological disorders constituted a Public Health Emergency of International Concern (PHEIC). In response, WHO in collaboration with UNICEF and a working group of independent subject matter experts developed a Zika virus vaccine Target Product Profile (TPP) for use in an emergency, or in a future outbreak scenario. The drafting process of the Zika virus vaccine TPP included the opportunity for public comment, as well as consultation with epidemiologists, flavivirus vaccine subject matter experts, vaccine developers and global regulators to consider the regulatory expectations and potential emergency use pathways for a vaccine with the characteristics described in the TPP. This report summarizes an expert consultation held 6-7 June 2016 on the regulatory considerations for a Zika vaccine for emergency use.",
keywords = "Vaccine regulation, Zika vaccines, Zika virus",
author = "Vannice, {K. S.} and Giersing, {B. K.} and Kaslow, {D. C.} and E. Griffiths and H. Meyer and A. Barrett and Durbin, {A. P.} and D. Wood and J. Hombach",
year = "2019",
month = "11",
day = "28",
doi = "10.1016/j.vaccine.2016.10.034",
language = "English (US)",
volume = "37",
pages = "7443--7450",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "50",

}

TY - JOUR

T1 - Meeting Report

T2 - WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency

AU - Vannice, K. S.

AU - Giersing, B. K.

AU - Kaslow, D. C.

AU - Griffiths, E.

AU - Meyer, H.

AU - Barrett, A.

AU - Durbin, A. P.

AU - Wood, D.

AU - Hombach, J.

PY - 2019/11/28

Y1 - 2019/11/28

N2 - On 1 February 2016, in the context of the ongoing Zika virus epidemic, the WHO declared that the recently reported clusters of microcephaly and other neurological disorders constituted a Public Health Emergency of International Concern (PHEIC). In response, WHO in collaboration with UNICEF and a working group of independent subject matter experts developed a Zika virus vaccine Target Product Profile (TPP) for use in an emergency, or in a future outbreak scenario. The drafting process of the Zika virus vaccine TPP included the opportunity for public comment, as well as consultation with epidemiologists, flavivirus vaccine subject matter experts, vaccine developers and global regulators to consider the regulatory expectations and potential emergency use pathways for a vaccine with the characteristics described in the TPP. This report summarizes an expert consultation held 6-7 June 2016 on the regulatory considerations for a Zika vaccine for emergency use.

AB - On 1 February 2016, in the context of the ongoing Zika virus epidemic, the WHO declared that the recently reported clusters of microcephaly and other neurological disorders constituted a Public Health Emergency of International Concern (PHEIC). In response, WHO in collaboration with UNICEF and a working group of independent subject matter experts developed a Zika virus vaccine Target Product Profile (TPP) for use in an emergency, or in a future outbreak scenario. The drafting process of the Zika virus vaccine TPP included the opportunity for public comment, as well as consultation with epidemiologists, flavivirus vaccine subject matter experts, vaccine developers and global regulators to consider the regulatory expectations and potential emergency use pathways for a vaccine with the characteristics described in the TPP. This report summarizes an expert consultation held 6-7 June 2016 on the regulatory considerations for a Zika vaccine for emergency use.

KW - Vaccine regulation

KW - Zika vaccines

KW - Zika virus

UR - http://www.scopus.com/inward/record.url?scp=85075226863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075226863&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2016.10.034

DO - 10.1016/j.vaccine.2016.10.034

M3 - Article

C2 - 27916410

AN - SCOPUS:85075226863

VL - 37

SP - 7443

EP - 7450

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 50

ER -